💊 Medication
GLP-1 Drugs
GLP-1 and GLP-1/GIP receptor agonists — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide. Strong evidence they cause major weight loss and cut cardiovascular events, with tirzepatide outperforming semaglutide, and they resolve fatty-liver steatohepatitis. Trade-offs: frequent GI side effects, disproportionate lean-mass loss, and substantial weight regain after stopping — they're chronic therapy.
5 well-supported · 0 disputed. This shows how settled each sub-question is, not whether GLP-1 Drugs is "good." Direction lives in each claim below.
The 5 claims about GLP-1 Drugs
Each keeps its own verdict — we never average them away.
Do GLP-1 weight-loss/diabetes drugs actually lower the risk of heart attacks and strokes?
Strong support Yes — across multiple large randomized trials and meta-analyses they cut major cardiovascular events by roughly 12-20%, in people with diabetes and (per SELECT) in obesity without diabetes.
Do GLP-1 drugs commonly cause stomach and GI side effects?
Strong support Very commonly nausea, vomiting, diarrhea and constipation — usually mild/transient and tied to delayed gastric emptying — with a small but real increase in rarer events like gastroparesis and bowel obstruction.
If I stop a GLP-1 drug, will I gain the weight back?
Strong support Yes — trials and pooled data consistently show people regain about two-thirds of lost weight within ~1 year of stopping, so these drugs work like chronic therapy rather than a cure.
Does tirzepatide (Zepbound/Mounjaro) take off more weight than semaglutide (Wegovy/Ozempic)?
Strong support Yes — the head-to-head SURMOUNT-5 trial and network meta-analyses show tirzepatide produces several percentage points more weight loss than semaglutide.
Can GLP-1 drugs help fatty-liver disease (MASH/NASH), including the scarring?
Strong support Yes for resolving the inflammation — robustly shown for semaglutide and tirzepatide; the harder fibrosis (scarring) benefit was null in early phase-2 but reached significance in the large phase-3 ESSENCE trial.
Educational only, not medical advice. Hub descriptions are curated for honesty; see the methodology.